Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Placing gold markers in the area where the tumor was removed may help doctors better direct radiation therapy and help reduce the risk of cancer recurrence. PURPOSE: This phase I trial is studying how well radiation therapy using gold markers works in treating women with early-stage breast cancer.

Key facts

Study ID

NCT00749437

Run by

University of Medicine and Dentistry of New Jersey

People needed

34

Starts

2008-10-01

Expected to finish

2010-07-01

Last updated by the study team

2012-06-14

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed ductal carcinoma in situ or invasive carcinoma of the breast (including ductal, medullary, papillary, colloid [mucinous], or tubular histologies) meeting all of the following criteria:
• AJCC stage 0, I, or II (Tis, T1N0, or T2N0) disease with a lesion ≤ 3 cm treated with lumpectomy and either sentinel node biopsy or axillary dissection (if invasive carcinoma is present)
• Unifocal breast cancer (i.e., single focus that can be encompassed by one lumpectomy)
• Underwent or plan to undergo lumpectomy with placement of gold fiducial markers (markers placed concurrently with the surgery or on a later date)
• Patients who has underwent lumpectomy must meet all of the following criteria:
• Must be enrolled between 14-60 days from date of last surgery, and radiation must start within 15-80 days of date of last surgery
• Four to six gold fiducial markers placed in the tumor bed, delineating the margins of the lumpectomy cavity
• Negative, inked histologic margins of lumpectomy (> 1 mm) or re-excision specimen to be confirmed prior to radiation
• Margins are unacceptable if there is invasive or non-invasive tumor within 1 mm of the inked margin
• Negative post-excision mammography if malignancy-associated microcalcifications were initially present
• Hormone receptor status not specified

You may not qualify if…

• Evidence of suspicious microcalcifications in the breast prior to the start of radiation
• One or more positive axillary nodes or positive sentinel biopsy
• Distant metastases
• Invasive or extensive in-situ lobular carcinoma or non-epithelial breast malignancies such as sarcoma or lymphoma
• Proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy
• Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor
• Paget's disease of the nipple
• Skin involvement, regardless of tumor size
• PATIENT CHARACTERISTICS:
• Female
• Menopausal status not specified
• ECOG performance status 0-1
• Life expectancy ≥ 2 years
• Not pregnant or nursing
• No prior treated breast carcinoma within the past 5 years
• No collagen vascular diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis
• No co-existing medical conditions
• No patients with medical conditions that would preclude compliance with the trial, as determined by the investigator
• No other malignancy, except non-melanomatous skin cancer, within the past 5 years
• Disease-free interval from any prior carcinoma must be continuous
• No breast technically unsuitable for radiotherapy
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Concurrent tamoxifen citrate, anastrozole, or other hormonal therapy allowed
• Future chemotherapy allowed provided it is administered after the APBI and begins no earlier than 2 weeks after completion of radiotherapy

Where it is running

• Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.